BACKGROUND: Generation of suitable in vivo models is critical for understanding of processes associated with development and progression of prostate cancer (CaP). METHODS: Lymph nodes containing metastatic androgen-independent CaP were implanted into athymic mice. A xenograft designated LuCaP 35 and its hormone-independent variant LuCaP 35V were established and characterized. RESULTS: LuCaP 35 is an androgen-sensitive, prostate-specific antigen (PSA)-producing xenograft. It expresses the wild-type androgen receptor and exhibits deletions in chromosome 8p, but not in chromosome 10. The response of LuCaP 35 to androgen ablation is similar to that observed in man. Using recurring LuCaP 35 tumors we have also established an androgen-insensitive variant of LuCaP 35. CONCLUSIONS: The availability of hormone-dependent and -independent variants of LuCaP 35, which exhibit many properties analogous to those of CaP in man, provides an excellent model system to study the processes associated with development of androgen independence and to evaluate new treatment modalities. Copyright 2003 Wiley-Liss, Inc.
BACKGROUND: Generation of suitable in vivo models is critical for understanding of processes associated with development and progression of prostate cancer (CaP). METHODS: Lymph nodes containing metastatic androgen-independent CaP were implanted into athymic mice. A xenograft designated LuCaP 35 and its hormone-independent variant LuCaP 35V were established and characterized. RESULTS: LuCaP 35 is an androgen-sensitive, prostate-specific antigen (PSA)-producing xenograft. It expresses the wild-type androgen receptor and exhibits deletions in chromosome 8p, but not in chromosome 10. The response of LuCaP 35 to androgen ablation is similar to that observed in man. Using recurring LuCaP 35 tumors we have also established an androgen-insensitive variant of LuCaP 35. CONCLUSIONS: The availability of hormone-dependent and -independent variants of LuCaP 35, which exhibit many properties analogous to those of CaP in man, provides an excellent model system to study the processes associated with development of androgen independence and to evaluate new treatment modalities. Copyright 2003 Wiley-Liss, Inc.
Authors: Shihua Sun; Cynthia C T Sprenger; Robert L Vessella; Kathleen Haugk; Kathryn Soriano; Elahe A Mostaghel; Stephanie T Page; Ilsa M Coleman; Holly M Nguyen; Huiying Sun; Peter S Nelson; Stephen R Plymate Journal: J Clin Invest Date: 2010-07-19 Impact factor: 14.808
Authors: Ilsa M Coleman; Jeffrey A Kiefer; Lisha G Brown; Tiffany E Pitts; Peter S Nelson; Kristen D Brubaker; Robert L Vessella; Eva Corey Journal: Neoplasia Date: 2006-10 Impact factor: 5.715
Authors: Evan Y Yu; Hongli Li; Celestia S Higano; Neeraj Agarwal; Sumanta K Pal; Ajjai Alva; Elisabeth I Heath; Elaine T Lam; Shilpa Gupta; Michael B Lilly; Yoshio Inoue; Kim N Chi; Nicholas J Vogelzang; David I Quinn; Heather H Cheng; Stephen R Plymate; Maha Hussain; Catherine M Tangen; Ian M Thompson Journal: J Clin Oncol Date: 2015-04-06 Impact factor: 44.544
Authors: Theodore D Koreckij; Richard J Trauger; Robert Bruce Montgomery; Tiffany E M Pitts; Ilsa Coleman; Holly Nguyen; Chris L Reading; Peter S Nelson; Robert L Vessella; Eva Corey Journal: Neoplasia Date: 2009-11 Impact factor: 5.715
Authors: Akash Kumar; Thomas A White; Alexandra P MacKenzie; Nigel Clegg; Choli Lee; Ruth F Dumpit; Ilsa Coleman; Sarah B Ng; Stephen J Salipante; Mark J Rieder; Deborah A Nickerson; Eva Corey; Paul H Lange; Colm Morrissey; Robert L Vessella; Peter S Nelson; Jay Shendure Journal: Proc Natl Acad Sci U S A Date: 2011-09-26 Impact factor: 11.205
Authors: Bruce Montgomery; Peter S Nelson; Robert Vessella; Tom Kalhorn; David Hess; Eva Corey Journal: BMC Cancer Date: 2010-05-28 Impact factor: 4.430
Authors: Diping Wang; R Bruce Montgomery; Lucy J Schmidt; Elahe A Mostaghel; Haojie Huang; Peter S Nelson; Donald J Tindall Journal: Cancer Res Date: 2009-12-15 Impact factor: 12.701